New chief financial officer Thad Huston said that Galapagos was evaluating “various strategic options for Jyseleca,” the company’s only revenue source, given that the landscape for the JAK class in Europe “has changed significantly over the past six months.”

Kite’s senior director and head of medical affairs, Intercontinental Region, Tony Li, talks to Scrip about the company's efforts to enable timely and broad access to Yescarta in Singapore, where wider cancer drug procurement prices have declined following policy changes. A patient is already on course to being prepped for Kite's CAR-T cell therapy.

Paul Stoffels is continuing his transformation of Galapagos into a company with CAR-T and small molecule platforms and is aiming to seal more M&A deals before the end of this year.

Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.